with treatment success was: PPI-CA 62% (29/47; 95%CI 46-75%); ST 72% (70/97; 95%CI 62-81%); BMT 92% (56/61; 95%CI 82-97%) and 100% (15/15; 95%CI 82-100%) of those randomized to CAM. Of 68 participants treated outside the clinical trial with a follow-up UBT, the proportion with treatment success was: PPI-CA 41% (7/17; 95%CI 18-67%); ST 47% (8/17; 95%CI 23-72%); BMT 92% (15/18; 95%CI 59-96%), CAM 67% (2/3; 95%CI 9-99%)and AL 3/3(100%, 95%CI 37-100%), In 10 patients the treatment was unknown. Conclusions: While treatment success estimates from this treatment trial in Canadian Arctic communities are somewhat imprecise, results demonstrate superiority of bismuth based quadruple and non-bismuth quadruple (CAM) therapies to sequential or triple therapy. Compliance with follow up UBT testing is suboptimal.
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